CCDRD AG was part of the clinical development of the originator product and participated in global phase III developments.
Morover, CCDRD AG has discussed and verified the clinical development strategy for biosimilar Trasutzumab with the European regulators.
Clinical work – 2 phase III trials and pharmacokinetic study
Efficacy study, multicentric
Breast cancer patients
Efficacy study, multicentric
Breast cancer patients
Pharmacokinetic study, monocentric
Healthy volunteers